Equities Analysts Set Expectations for Geron Q1 Earnings

Geron Co. (NASDAQ:GERN) – B. Riley issued their Q1 2025 EPS estimates for shares of Geron in a research note issued on Wednesday, February 26th. B. Riley analyst K. Patel expects that the biopharmaceutical company will earn ($0.03) per share for the quarter. B. Riley has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. B. Riley also issued estimates for Geron’s Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at ($0.02) EPS.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). The company had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%.

A number of other brokerages have also recently weighed in on GERN. Scotiabank lowered their price target on Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a research report on Thursday. HC Wainwright downgraded Geron from a “buy” rating to a “neutral” rating in a report on Wednesday. Needham & Company LLC cut their price objective on shares of Geron from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday. Stifel Nicolaus decreased their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Barclays reiterated an “overweight” rating and set a $4.00 target price (down previously from $9.00) on shares of Geron in a research note on Thursday. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Geron presently has an average rating of “Moderate Buy” and a consensus target price of $5.68.

Geron Price Performance

NASDAQ:GERN opened at $1.74 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The company has a fifty day moving average price of $2.97 and a 200 day moving average price of $3.80. Geron has a one year low of $1.46 and a one year high of $5.34. The stock has a market cap of $1.05 billion, a P/E ratio of -5.44 and a beta of 0.53.

Institutional Trading of Geron

Institutional investors and hedge funds have recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new stake in shares of Geron during the 4th quarter valued at about $28,000. Integrated Wealth Concepts LLC purchased a new position in shares of Geron in the fourth quarter worth $36,000. GF Fund Management CO. LTD. bought a new position in shares of Geron during the 4th quarter valued at about $45,000. Fifth Lane Capital LP purchased a new stake in shares of Geron during the 4th quarter worth approximately $53,000. Finally, Readystate Asset Management LP purchased a new position in shares of Geron in the 3rd quarter worth $58,000. 73.71% of the stock is currently owned by institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.